Leerink Partners analyst Daina Graybosch has maintained their bullish stance on HOWL stock, giving a Buy rating yesterday.
Daina Graybosch from Leerink Partners has assigned a Buy rating to Werewolf Therapeutics (ticker: HOWL) for a number of reasons. Firstly, Graybosch believes that the market is not fully appreciating the preliminary Phase 1 solid tumor data for Werewolf’s lead program, WTX-124, which was presented at the recent Society for Immunotherapy of Cancer meeting. Despite being in the early stages, the initial clinical data aligns with the high expectations for WTX-124, indicating a distinctive clinical profile for the drug in treating advanced immunotherapy-sensitive tumors.
Furthermore, the preliminary safety, pharmacokinetic (PK), and biomarker data for WTX-124 provides crucial proof-of-mechanism for Werewolf’s broader INDUKINE platform. Graybosch highlighted that this has positive implications for Werewolf’s earlier-stage INDUKINE pipeline. Graybosch also mentioned that investors are likely waiting for the more comprehensive Phase 1 WTX-124 update in the first half of 2024 for confirmation of the early dose-response relationship with additional patients and dose levels. Given the near-term financing risk and focus on WTX-124, she does not anticipate the WTX-518 product nomination or preclinical INDUKINE updates in general, to generate investor excitement.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Werewolf Therapeutics (HOWL) Company Description:
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
Read More on HOWL:
- Werewolf Therapeutics reports Q3 EPS (23c), consensus (39c)
- Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Werewolf Therapeutics management to meet with Jefferies
- Werewolf Therapeutics price target raised to $15 from $12 at Jefferies
- Werewolf present preliminary data from Phase 1/1b trial for WTX-124
